Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNDX 
Syndax Pharmaceuticals Inc (SNDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SNDX (1-star) is a SELL. SELL since 1 days. Simulated Profits (19.65%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $37.69
1 Year Target Price $37.69
| 9 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.34% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.30B USD | Price to earnings Ratio - | 1Y Target Price 37.69 |
Price to earnings Ratio - | 1Y Target Price 37.69 | ||
Volume (30-day avg) 12 | Beta 0.68 | 52 Weeks Range 8.58 - 22.50 | Updated Date 10/17/2025 |
52 Weeks Range 8.58 - 22.50 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -182.71% |
Management Effectiveness
Return on Assets (TTM) -39.5% | Return on Equity (TTM) -113.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 862999349 | Price to Sales(TTM) 16.64 |
Enterprise Value 862999349 | Price to Sales(TTM) 16.64 | ||
Enterprise Value to Revenue 11.07 | Enterprise Value to EBITDA -105.26 | Shares Outstanding 86141862 | Shares Floating 72737327 |
Shares Outstanding 86141862 | Shares Floating 72737327 | ||
Percent Insiders 1.29 | Percent Institutions 120.9 |
Upturn AI SWOT
Syndax Pharmaceuticals Inc
Company Overview
History and Background
Syndax Pharmaceuticals Inc. was founded in 2005. It's a biopharmaceutical company focused on developing therapies for the treatment of cancer. Key milestones include successful clinical trials, partnerships, and regulatory approvals.
Core Business Areas
- Oncology Drug Development: Syndax focuses on developing and commercializing novel cancer therapies. Their pipeline includes drugs targeting specific genetic mutations and immune-oncology approaches.
Leadership and Structure
Syndax Pharmaceuticals Inc. has a leadership team comprised of experienced executives in drug development, regulatory affairs, and commercialization. The organizational structure is typical of a publicly traded biotechnology company.
Top Products and Market Share
Key Offerings
- Revumenib: Revumenib is a medicine used to treat adult and pediatric patients 1 month and older with relapsed or refractory KMT2Ar acute leukemia. It has significant market share in its specific treatment niche within the leukemia space. Competitors: Other leukemia treatment options, including chemotherapy and other targeted therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in oncology, is highly competitive and characterized by high R&D costs, stringent regulatory requirements, and a need for innovative therapies. The sector is experiencing growth due to aging populations and increased cancer incidence.
Positioning
Syndax is positioned as a developer of targeted cancer therapies. Its competitive advantage lies in its focus on specific genetic mutations and its potential to deliver more effective treatments with fewer side effects.
Total Addressable Market (TAM)
The total addressable market for Syndax's drugs is substantial, particularly within specific leukemia subtypes. The company is targeting niche markets within the broader oncology space.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Strong intellectual property
- Experienced management team
- Focus on targeted therapies
Weaknesses
- Limited product portfolio
- Reliance on clinical trial success
- High R&D expenses
- Dependence on regulatory approvals
Opportunities
- Expansion of pipeline
- Partnerships and collaborations
- New drug approvals
- Market growth in oncology
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- GILD
Competitive Landscape
Syndax faces intense competition from larger, well-established pharmaceutical companies. Its advantage lies in its targeted therapies, but its smaller size is a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Syndax's historical growth is linked to its success in advancing its drug pipeline. The company's progress is closely watched by investors.
Future Projections: Future growth projections depend on the successful development and commercialization of its drugs, as well as market conditions and regulatory approvals. Analyst estimates are critical.
Recent Initiatives: Recent strategic initiatives likely include clinical trial advancements, regulatory submissions, and partnerships to expand its reach.
Summary
Syndax Pharmaceuticals is a biotechnology company with a focus on targeted cancer therapies. Its strengths lie in its novel drug candidates and experienced management, but it faces challenges due to its limited product portfolio and reliance on clinical trial success. The company needs to capitalize on pipeline expansion and partnerships while navigating the competitive landscape and regulatory hurdles. The company has a very specific treatment niche within the leukemia space, which will help drive TAM
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The data provided is based on available information, which may be subject to change. Investment decisions should be made based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Syndax Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-03-03 | CEO & Director Mr. Michael A. Metzger M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 270 | Website https://syndax.com |
Full time employees 270 | Website https://syndax.com | ||
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.